Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications - Wikidata - awgldk - TriplyDB

Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications

Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications

http://www.wikidata.org/entity/Q35141566

about

Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement Medicaid prescription limits: policy trends and comparative impact on utilization.Association Between Severe Hypoglycemia and Cardiovascular Disease Risk in Japanese Patients With Type 2 Diabetes Completeness of prescription information in US commercial claims databases Diabetes and cancer II: role of diabetes medications and influence of shared risk factors.Prescription medication burden in patients with newly diagnosed diabetes: a SUrveillance, PREvention, and ManagEment of Diabetes Mellitus (SUPREME-DM) study.Assessing the effect of treatment duration on the association between anti-diabetic medication and cancer risk Initial therapy, persistence and regimen change in a cohort of newly treated type 2 diabetes patients.Trends in Antihyperglycemic Medication Prescriptions and Hypoglycemia in Older Adults: 2002-2013 Sulfonylurea use and the risk of hospital readmission in patients with type 2 diabetes.Diabetes treatment intensification and associated changes in HbA1c and body mass index: a cohort study.Geographic variation in pharmacotherapy decisions for U.S. Medicare enrollees with diabetes.Metformin Does Not Suppress Serum Thyrotropin by Increasing Levothyroxine Absorption Changing Patterns of Glucose-Lowering Medication Use in VA Nursing Home Residents With Diabetes, 2005 to 2011.Comparison of clinical characteristics in patients with type 2 diabetes among whom different antihyperglycemic agents were prescribed as monotherapy or combination therapy by diabetes specialists.Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis.Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE).Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis.Effectiveness of sulphonylureas in the therapy of diabetes mellitus type 2 patients: an observational cohort study.Prescribing attitudes, behaviors and opinions regarding metformin for patients with diabetes: a focus group study.Cost-effectiveness of MODY genetic testing: translating genomic advances into practical health applications.Ameliorative effects of rutin against metabolic, biochemical and hormonal disturbances in polycystic ovary syndrome in rats.Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum.Trends in insulin initiation and treatment intensification among patients with type 2 diabetes.Comparison of baseline characteristics and clinical course in Japanese patients with type 2 diabetes among whom different types of oral hypoglycemic agents were chosen by diabetes specialists as initial monotherapy (JDDM 42).A review of the efficacy and safety of oral antidiabetic drugs Clinical relevance of target identity and biology: implications for drug discovery and development.Metformin Safety Warnings and Diabetes Drug Prescribing Patterns for Older Nursing Home Residents.Comparative Safety of Sulfonylurea and Metformin Monotherapy on the Risk of Heart Failure: A Cohort Study Academic Detailing in Diabetes: Using Outreach Education to Improve the Quality of Care.Progressing From Metformin to Sulfonylureas or Meglitinides.Differences in the Use and Quality of Antidiabetic Therapies in Mexican American and Non-Hispanic Whites With Uncontrolled Type 2 Diabetes in the US: NHANES 2003-2012.A Comparison of the Use of Clinical-Guideline-Recommended Antihypertensive Regimens in Mexican American, Non-Hispanic Black, and Non-Hispanic White Adults With Type 2 Diabetes and Hypertension in the United States: NHANES 2003-2012.Prevalence and Predictors of Metformin Prescribing in Adults with Type 2 Diabetes Mellitus: A National Cross-Sectional Study.Early glycaemic control among patients with type 2 diabetes and initial glucose-lowering treatment: a 13-year population-based cohort study.Gluc-HET, a complementary chick embryo model for the characterization of antidiabetic compounds.Costs and Treatment Pathways for Type 2 Diabetes in the UK: A Mastermind Cohort Study.Sulfonylurea: Personalized Medicine for Type 2 Diabetes.Prescribing patterns and adherence to medication among South-Asian, Chinese and white people with type 2 diabetes mellitus: a population-based cohort study.

P2860

Q26751138-D00A0749-5DAA-4443-8177-C8228944E595 Q26783199-D5562921-BA05-4B2D-BB5A-7E5B17FDFBA3 Q27306989-A5E77F42-254E-42C7-B445-19F27D51E296 Q28073762-6485655A-71BF-4980-B4CB-300BF1F5994A Q33575568-FB9D6DC3-96E4-4082-81F8-B1ECE07B4F02 Q34069086-28388B24-DCCB-48B5-BB7F-8EE88AE199D5 Q34167629-9A0E348A-10E4-47D5-8ED1-33485508589B Q34565654-269ED7F3-511F-4E53-B2CA-9005254BC436 Q35684836-2DF1CF50-AE41-4C49-A417-B4B23FEFB575 Q35763657-25E43410-A08D-4885-9EFE-D1F3A23C2097 Q35898272-7D0D4E3C-5B0D-4392-B85E-D317121FDB32 Q36038607-C22A4C72-1C9D-4799-91EC-4FB249446761 Q36098838-9930DAED-36FF-47D3-95FE-0997BCC8D2E3 Q36108068-E2D4E887-4BD8-49BF-9C87-E0BEBAFC0750 Q36122492-228B2AD0-8C6C-4543-908A-C2DABB0D6477 Q36637980-F440AC38-7E8A-4584-AB47-F0645B31EA3E Q36755942-81B1A623-6DE6-480E-9BED-96933E7A84C5 Q37022623-D10BCDE5-DA8F-4977-8CFE-A22E062D1F9F Q37037308-C743B34A-6BCA-4867-A8B9-EB6B68F5F50A Q37145172-7765613C-44C3-4FFC-B0D1-858A562C68F1 Q37196371-B8CA7112-3CFA-4236-94B4-F33D2831CC47 Q37403160-2CEFFFEF-B9A2-47D4-A00F-011FC9935DCE Q37480891-55C9D2FE-7876-4221-B2D0-BEA663109EE1 Q37517909-8120CD7D-EDBF-44A3-A642-A53AC415AE48 Q37549653-832FB9FE-F316-40B1-9358-28C99CB7D705 Q37656347-DD299D81-4065-4FE7-8C88-DEAE8E270843 Q38067491-445609D3-5394-4DC3-A373-7855C3E5FFB4 Q38147723-955E254E-3F41-4204-B794-68C1B05DDBF0 Q38694106-2493FAF6-C20D-4192-B67B-9336222B2F38 Q38829782-7376F072-1601-44B5-A5E7-FFE7F6854D93 Q38944213-7A4F1A14-4D51-4792-A38A-80F274A1CA57 Q38952882-031EB7BE-C27D-468C-9688-3646A81C099F Q38984724-183748C8-26B3-4E59-940E-3B31B43F672D Q39398379-DBF33CED-6F4D-4C3A-A8A7-5438DD954BB6 Q39747129-D1FB32B1-9D0C-491C-BBDC-BF77A5A2B42E Q40992298-F150A13C-EC77-490B-AC9D-B9853B6DDC07 Q41255366-F9FDF1EC-E1AF-4492-B9A9-883561977FE9 Q42371740-D898B7AF-E66C-4EEB-8A05-976D959FAB82 Q42929953-70606480-E068-4624-8138-2BFF552B8373 Q44121406-42AA51BB-8A41-4AC3-9420-2663BF35FE7F

P2860

Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications

http://www.wikidata.org/entity/Q35141566

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Patterns of medication initiat ...... quality and cost implications

@ast

Patterns of medication initiat ...... quality and cost implications

@en

type

label

Patterns of medication initiat ...... quality and cost implications

@ast

Patterns of medication initiat ...... quality and cost implications

@en

prefLabel

Patterns of medication initiat ...... quality and cost implications

@ast

Patterns of medication initiat ...... quality and cost implications

@en

P1433

Q35141566-48466F6E-D6BC-42A4-ABAD-8B15392D3040

P1476

Q35141566-6136B8EC-0F3B-450D-8917-77201324AF08

P2093

Q35141566-006A2136-388B-41BE-B8FD-EE62996C0C2E

Q35141566-5EF9985B-8DAE-430C-AE9C-99DD795F585D

Q35141566-77CDEEFF-2E89-4506-A030-ADC15411C153

Q35141566-C4F701F9-1A55-4595-9A05-4525DDACC01D

Q35141566-C706783E-277D-4C59-9F99-4740BAA5CA15

Q35141566-E7F96EF6-19A0-4CC3-8BA7-149CA2911580

Q35141566-F25E59CD-AF40-45E8-9BD2-963C834C8B4E

Q35141566-FCACF1E2-1C4B-415E-93D3-6AAE42935AB5

Q35141566-FE5FAB7D-9F7E-43E9-97BE-7320B0A37924

P2860

Q35141566-010C4611-3365-4E64-81BF-206A2231C44B

Q35141566-102958FF-926E-440A-AC4B-460A25A22784

Q35141566-189B3409-21CF-411B-9858-EF1761314745

Q35141566-26C3818E-158A-4AC0-B1D5-09A5402D15F9

Q35141566-34C88D8D-F11A-4ECC-B2E1-54A3D84D6A06

Q35141566-7782EDBA-C99C-4874-8825-C894A0A7C85F

Q35141566-7BFD4E4E-B0F6-474F-9F46-7EAD06E77546

Q35141566-A567A6A9-F03D-4AB1-B1B3-B2C229D4580F

Q35141566-BA88B6F7-E716-4D79-B9ED-F27062584E62

Q35141566-F6E65B8D-1CFE-4EB5-8FE8-331C73FC65C7

P304

Q35141566-3D7A27C0-6AD4-401D-AFF4-73E806265686

P31

Q35141566-7FE7C85A-FECF-4C6C-8B67-6F0113CEE78F

P356

Q35141566-41B0262D-E5B9-4B40-862C-A57C92C9AF86

P407

Q35141566-00485D9E-BC84-4D8B-A1E7-9116B6793F22

P433

Q35141566-4FD4B507-AC3C-47AC-B43E-C0EFCE6331DB

P478

Q35141566-C3CD29ED-7818-4D1D-9599-828217F460A3

P577

Q35141566-DC563FC3-06DB-42CD-A8C1-AA7FC49F08CF

P5875

Q35141566-CB7E2841-E3F6-427F-AB59-6905427CDD77

P698

Q35141566-C3F4E9DA-81D6-477D-95AF-2FD9FCD1BC73

P932

Q35141566-571900EE-59D9-40EF-8794-19507C012253

P356

J.AMJMED.2011.07.033

P1433

The American Journal of Medicine

P1476

Patterns of medication initiat ...... quality and cost implications

@en

P2093

Jerry Avorn

http://www.w3.org/2001/XMLSchema#string

Joshua N Liberman

http://www.w3.org/2001/XMLSchema#string

Juliana Pakes

http://www.w3.org/2001/XMLSchema#string

Michael A Fischer

http://www.w3.org/2001/XMLSchema#string

Nihar R Desai

http://www.w3.org/2001/XMLSchema#string

Niteesh K Choudhry

http://www.w3.org/2001/XMLSchema#string

Sebastian Schneeweiss

http://www.w3.org/2001/XMLSchema#string

Troyen A Brennan

http://www.w3.org/2001/XMLSchema#string

William H Shrank

http://www.w3.org/2001/XMLSchema#string

P2860

Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Economic costs of diabetes in the U.S. In 2007.

Patients' perceptions of generic medications.

Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S.

Regulatory action on rosiglitazone by the U.S. Food and Drug Administration.

P304

302.e1-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.AMJMED.2011.07.033

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

125

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221838521

http://www.w3.org/2001/XMLSchema#string

P698

22340932

http://www.w3.org/2001/XMLSchema#string

P932

4347833

http://www.w3.org/2001/XMLSchema#string